Press releases
-
Angelini Pharma launches new crowd-sourcing challenge to fund innovative solutions to drug adherence and management of epilepsy
Angelini Pharma will award 25,000 $, with the potential of further awards not less than $5,000.
-
Angelini Pharma and SK Biopharmaceuticals announce treatment of more than 100,000 patients globally with Innovative Anti-Seizure Medication Cenobamate
Milestone coincides with expansion of cenobamate access to more than 100 markets worldwide
-
New Headway Report
Eco-anxiety, characterized by a pervasive fear of climate change and its consequences, has emerged as a significant concern for mental health, particularly among young people.
-
-
Announced today the publication of the second edition of the Headway – A new roadmap in Brain Health: Focus Epilepsy Report
The report shows up to 40% of European patients living with epilepsy are receiving inadequate treatment to control seizures.
-
Angelini Pharma launches LIFE-GREENAPI as part of its green transition strategy
LIFE-GREENAPI will deploy a more efficient, greener, and innovative process for producing Active Pharmaceutical Ingredients (APIs), by switching from batch to flow chemistry technology.
-
-
EMA recommends extension of dalbavancin indication in children
Angelini Pharma announces that the European Commission (EC) has approved the extension of the indication of Xydalba® (dalbavancin) for the treatment of acute bacterial skin and soft tissue infections in children.
-
Angelini Industries appoints Jacopo Andreose new CEO of Angelini Pharma
Jacopo Andreose, who will take on the role from February 6, has over twenty years of experience in top management positions in the pharmaceutical industry.
-
New Headway Report
Ukraine–Russia conflict and climate change may lead to a new wave of mental health disorders in the coming months.
